Assessment of the pharmacodynamic properties of antimalarial drugs
Issued Date
2026-04-30
Resource Type
eISSN
14712970
Scopus ID
2-s2.0-105037562461
Pubmed ID
42057719
Journal Title
Philosophical Transactions of the Royal Society of London Series B Biological Sciences
Volume
381
Issue
1949
Rights Holder(s)
SCOPUS
Bibliographic Citation
Philosophical Transactions of the Royal Society of London Series B Biological Sciences Vol.381 No.1949 (2026)
Suggested Citation
White N.J. Assessment of the pharmacodynamic properties of antimalarial drugs. Philosophical Transactions of the Royal Society of London Series B Biological Sciences Vol.381 No.1949 (2026). doi:10.1098/rstb.2024.0339 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/116612
Title
Assessment of the pharmacodynamic properties of antimalarial drugs
Author(s)
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Quantifying therapeutic responses in clinical malaria is easier than for most other infections as the intraerythrocytic parasites can be counted by microscopy or estimated using quantitative PCR. In treating the blood-stage of malaria, between 107 and 1013 parasites undergo a first-order decline in densities at a rate determined by the concentrations and potency of the antimalarial drug. A simple conceptual framework based on total intravascular parasite biomass and standard sigmoid concentration-effect relationships for parasite killing explains most, but not all, aspects of antimalarial therapeutic responses, and it has proved very useful in designing chemoprevention and treatment regimens and in understanding the selection and spread of resistance. Drugs acting on younger circulating ring-stage asexual parasites (artemisinins, cipargamin, ganaplacide) provide rapid parasite clearance, which translates into faster clinical recoveries and a life-saving benefit in severe malaria. Artemisinin-sensitive Plasmodium falciparum densities decline with a half-life (PC1/2) of usually less than 5 h. Many antimalarial drugs are eliminated slowly and provide protracted exposures, which allows full treatment to be administered in 3 days, and also provides chemosuppression of newly acquired infections for 1 month. Greater availability of drug measurement in malaria-endemic areas would facilitate the field assessment of antimalarial drugs. This article is part of the Theo Murphy meeting issue 'Evaluating anti-infective drugs'.